PMV Pharmaceuticals stock: PYNNACLE results set for ENA presentation

PMV Pharmaceuticals said on November 4, 2026, that updated results from the pivotal Phase 2 portion of its PYNNACLE trial will be featured in a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The announcement was published by GlobeNewswire.

Clinical Data Moves Into Focus

The session is scheduled for November 20, 2026, at 15:00 CET in Barcelona. Alison M. Schram, M.D., of Memorial Sloan Kettering Cancer Center, is set to present the findings in Plenary Session 7 under abstract number 12LBA.

PMV said the presentation will include updated data from all PYNNACLE cohorts, with emphasis on efficacy across tumor types and the ovarian cancer primary analysis population. The company has not released the presentation results in the announcement, so the event remains a future clinical readout rather than a new efficacy result.

Rezatapopt Drives the Pipeline

Rezatapopt, also known as PC14586, is an oral small-molecule p53 reactivator designed to bind selectively to the p53 Y220C mutant protein and restore its tumor-suppressor function. The ongoing Phase 1/2 PYNNACLE trial evaluates the candidate in patients with advanced solid tumors carrying a TP53 Y220C mutation.

The Phase 2 portion is a registrational, single-arm expansion basket trial covering ovarian, lung, breast and endometrial cancers as well as other solid tumors. PMV said the trial is being conducted across approximately 70 sites and is designed to evaluate efficacy at the recommended Phase 2 dose.

Company Profile and Competitive Field

PMV Pharmaceuticals is a Princeton, New Jersey-based precision oncology company developing small-molecule, tumor-agnostic therapies that target p53 mutations. Its lead program is rezatapopt, while the company focuses on restoring the normal function of selected mutant p53 proteins. The corporate profile is available from PMV Pharmaceuticals.

PMV operates as a specialized clinical-stage biotechnology issuer within the broader precision-oncology field. A peer comparison published by Trade Ideas lists Amgen, Moderna, Revolution Medicines, Roivant Sciences and BioNTech among its comparison companies, spanning larger and more diversified biotechnology and pharmaceutical groups.

The broader U.S. equity market provides the market backdrop for clinical-stage biotechnology shares; see S&P 500 market coverage.

More clinical updates and company developments are available in more news and analyses on PMV Pharmaceuticals stock.